Candel Therapeutics, Inc.
Candel reveals promising data on prostate cancer treatment.
1 source·30/09, 12:12·finviz.com
Candel hosting R&D Day showcasing pipeline insights.
1 source·05/12, 13:32·sec.gov
10-Q form submitted!
1 source·13/11, 13:32·sec.gov
Candel Therapeutics announces Q3 2025 financial results.
1 source·13/11, 13:16·sec.gov
Positive clinical trial results for CAN-3110 announced.
1 source·14/10, 12:24·sec.gov
Lease agreement extended for three more years.
1 source·21/08, 20:32·sec.gov
10-Q form submitted!
1 source·14/08, 12:12·sec.gov
Candel Therapeutics announces quarterly financial results.
1 source·14/08, 12:08·sec.gov
Candel Therapeutics announces $15 million stock offering.
1 source·24/06, 13:28·sec.gov
New CFO appointed, potentially strengthening financial oversight.
1 source·23/06, 12:16·sec.gov
CADL Slips Despite Encouraging Prostate Cancer Drug Data Retail Believes Stock Is Clearly A Buy And Hold
finviz·yahoo.com·30/09, 15:00
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
finviz·finviz.com·30/09, 12:30
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
finviz·finviz.com·30/09, 12:05
Candel Therapeutics, Inc. (CADL)'s CAN-2409 Advances with FDA RMAT Status for Localized Prostate Cancer
·finviz.com·29/05, 00:00
Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation
·finviz.com·27/05, 12:09